Khaldoun Almhanna, MD, MPH

Where You Are:
Khaldoun Almhanna, MD, MPH

Assistant Member

Office  (813) 745-7257

Education And Training
  • Fellow, Cleveland Clinic, 2008 - Hematology-Oncology
  • Resident, Oakwood Hospital and Medical Center, 2005 - Internal Medicine
  • MPH, Case Western Reserve University, 2001
  • Intern, Damascus University Hospital, 1996 - Internal Medicine
  • MD, Damascus University, 1994


Phase I/II trials in Gastrointestinal cancers, specifically esophageal and gastric cancer focusing on personalized targeted therapy.

  • Shridhar R, Almhanna K, Hoffe SE, Fulp W, Weber J, Chuong MD, Meredith KL. Increased survival associated with surgery and radiation therapy in metastatic gastric cancer: A Surveillance, Epidemiology, and End Results database analysis. Cancer. 2013 May;119(9):1636-1642. Pubmedid: 23361968.
  • Almhanna K, Meredith KL, Hoffe SE, Shridhar R, Coppola D. Targeting the human epidermal growth factor receptor 2 in esophageal cancer. Cancer Control. 2013 Apr;20(2):111-116. Pubmedid: 23571701.
  • Shridhar R, Almhanna K, Meredith KL, Biagioli MC, Chuong MD, Cruz A, Hoffe SE. Radiation therapy and esophageal cancer. Cancer Control. 2013 Apr;20(2):97-110. Pubmedid: 23571700.
  • Shridhar R, Hoffe SE, Almhanna K, Weber JM, Chuong MD, Karl RC, Meredith K. Lymph Node Harvest in Esophageal Cancer After Neoadjuvant Chemoradiotherapy. Ann Surg Oncol. 2013 Apr. Pubmedid: 23625142.
  • Almhanna K, Shridhar R, Meredith KL. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: is there a standard of care?. Cancer Control. 2013 Apr;20(2):89-96. Pubmedid: 23571699.
  • Vignesh S, Hoffe SE, Meredith KL, Shridhar R, Almhanna K, Gupta AK. Endoscopic Therapy of Neoplasia Related to Barrett's Esophagus and Endoscopic Palliation of Esophageal Cancer. Cancer Control. 2013 Apr;20(2):117-129. Pubmedid: 23571702.
  • Wong JY, Shridhar R, Almhanna K, Hoffe SE, Karl RC, Meredith KL. The impact of body mass index on esophageal cancer. Cancer Control. 2013 Apr;20(2):138-143. Pubmedid: 23571704.
  • Pimiento JM, Weber J, Hoffe SE, Shridhar R, Almhanna K, Vignesh S, Karl RC, Meredith KL. Outcomes Associated with Surgery for T4 Esophageal Cancer. Ann Surg Oncol. 2013 Mar. Pubmedid: 23504118.
  • Melis M, Weber J, Shridhar R, Hoffe S, Almhanna K, Karl RC, Meredith KL. Body mass index and perioperative complications after oesophagectomy for adenocarcinoma: a systematic database review. BMJ Open. 2013;3(5). Pubmedid: 23645908. Pmcid: PMC3646172.
  • Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol. 2012 Oct;18(40):5679-5687. Pubmedid: 23155307.
  • Almhanna K, El-Rayes B, Sethi S, Dyson G, Heilbrun L, Philip PA, Sarkar F. Association between COX-2 expression and effectiveness of COX-2 inhibitors in a phase II trial in patients with metastatic colorectal adenocarcinoma. Anticancer Res. 2012 Aug;32(8):3559-3563. Pubmedid: 22843946.
  • Shridhar R, Hayman T, Hoffe SE, Weber J, Almhanna K, Chuong M, Karl RC, Meredith KL. Body mass index and survival in esophageal adenocarcinoma treated with chemoradiotherapy followed by esophagectomy. J Gastrointest Surg. 2012 Jul;16(7):1296-1302. Pubmedid: 22399271.
  • Dittrick GW, Weber JM, Shridhar R, Hoffe S, Melis M, Almhanna K, Barthel J, McLoughlin J, Karl RC, Meredith KL. Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy. Ann Surg Oncol. 2012 May;19(5):1678-1684. Pubmedid: 22045465.
  • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May;48(7):997-1003. Pubmedid: 22445247.
  • Almhanna K. Targeted therapy for gastric adenocarcinoma. Adv Pharmacol. 2012;65:437-470. Pubmedid: 22959034.
  • Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011 Dec;31(12):4387-4392. Pubmedid: 22199303.
  • Almhanna K, Philip PA. Defining new paradigms for the treatment of pancreatic cancer. Curr Treat Options Oncol. 2011 Jun;12(2):111-125. Pubmedid: 21461670.
  • El-Rayes BF, Jasti P, Severson RK, Almhanna K, Philip PA, Shields A, Zalupski M, Heilbrun LK. Impact of race, age, and socioeconomic status on participation in pancreatic cancer clinical trials. Pancreas. 2010 Oct;39(7):967-971. Pubmedid: 20467351.
  • Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. Am J Transl Res. 2010 Sep;3(1):28-47. Pubmedid: 21139804. Pmcid: PMC2981424.
  • Kim R, Tsao R, Tan A, Byrne M, Almhanna K, Lazaryan A, Elson P, Pelley RJ. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators. J Gastrointest Surg. 2010 Jul;14(7):1159-1169. Pubmedid: 20446118.
  • Azmi AS, Philip PA, Almhanna K, Beck FW, Sarkar FH, Mohammad RM. MDM2 inhibitors for pancreatic cancer therapy. Mini Rev Med Chem. 2010 Jun;10(6):518-526. Pubmedid: 20377522.
  • Almhanna K, Wongchaowart N, Sweetenham J. Intracerebral Hodgkin's lymphoma in a patient with chronic lymphocytic leukemia/small lymphocytic lymphoma: a case report and literature review. Cancer Invest. 2009 Feb;27(2):215-220. Pubmedid: 19235595.
  • Almhanna K, Kim R. Second-line therapy for gemcitabine-refractory pancreatic cancer: is there a standard?. Oncology (Williston Park). 2008 Sep;22(10):1176-1183. Pubmedid: 18935928.
  • Almhanna K, Pelley RJ, Thomas Budd G, Davidson J, Moore HC. Subcutaneous implantable venous access device erosion through the skin in patients treated with anti-vascular endothelial growth factor therapy: a case series. Anticancer Drugs. 2008 Feb;19(2):217-219. Pubmedid: 18176119.
  • Saif MW, Hashmi S, Zelterman D, Almhanna K, Kim R. Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review. Int J Colorectal Dis. 2008 Feb;23(2):139-145. Pubmedid: 17909820.
  • Almhanna K, Kalmadi S, Pelley R, Kim R. Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?. Oncology (Williston Park). 2007 Aug;21(9):1116-1122. Pubmedid: 17910314.
  • Almhanna K, Khan P, Schaldenbrand M, Momin F. Sideroblastic anemia after bariatric surgery. Am J Hematol. 2006 Feb;81(2):155-156. Pubmedid: 16432847.
  • Chavez JC, Almhanna K, Berti-Mattera LN. Transient expression of hypoxia-inducible factor-1 alpha and target genes in peripheral nerves from diabetic rats. Neurosci Lett. 2005 Feb;374(3):179-182. Pubmedid: 15663958.
  • Almhanna K, Palanichamy N, Sharma M, Hobbs R, Sil A. Unilateral brachial plexopathy associated with West Nile virus meningoencephalitis. Clin Infect Dis. 2003 Jun;36(12):1629-1630. Pubmedid: 12802774.
  • Almhanna K, Wilkins PL, Bavis JR, Harwalkar S, Berti-Mattera LN. Hyperglycemia triggers abnormal signaling and proliferative responses in Schwann cells. Neurochem Res. 2002 Nov;27(11):1341-1347. Pubmedid: 12512939.
  • Berti-Mattera LN, Harwalkar S, Hughes B, Wilkins PL, Almhanna K. Proliferative and morphological effects of endothelins in Schwann cells: roles of p38 mitogen-activated protein kinase and Ca(2+)-independent phospholipase A2. J Neurochem. 2001 Dec;79(6):1136-1148. Pubmedid: 11752055.
  • Berti-Mattera LN, Wilkins PL, Harwalkar S, Madhun Z, Almhanna K, Mattera R. Endothelins regulate arachidonic acid release and mitogen-activated protein kinase activity in Schwann cells. J Neurochem. 2000 Dec;75(6):2316-2326. Pubmedid: 11080183.
TOOLS:   Font Size